Junction vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC health data API infrastructure connecting 500+ wearables and at-home lab tests for 140+ healthcare orgs; $18M Creandum Series A Mar 2025 supporting 2M+ connected devices and 500K+ tests annually competing with Validic and Terra API.
About
Junction is a United States-based health data infrastructure company — backed by Y Combinator with $18 million in Series A funding in March 2025 led by Creandum with participation from Point Nine, Amino Collective, and Inflect Health — providing digital health companies, research organizations, and healthcare technology platforms with a unified API infrastructure for collecting wearable device data (500+ supported devices including Apple Watch, Fitbit, Oura, Garmin, and continuous glucose monitors) and delivering at-home diagnostic test kits to patients with automated diagnostic data workflows that connect labs, wearables, and health systems. Founded and serving 140+ healthcare organizations including Found, Parsley Health, and Evidation, Junction supports 500,000+ lab tests annually and 2 million+ connected devices.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.